PMC:6562565 / 70996-71888 JSONTXT

{"project":"MyTest","denotations":[{"id":"31244820-27221704-35366445","span":{"begin":179,"end":182},"obj":"27221704"},{"id":"31244820-23776241-35366446","span":{"begin":184,"end":187},"obj":"23776241"},{"id":"31244820-24403862-35366447","span":{"begin":208,"end":211},"obj":"24403862"},{"id":"31244820-24403862-35366448","span":{"begin":230,"end":233},"obj":"24403862"},{"id":"31244820-23776241-35366449","span":{"begin":266,"end":269},"obj":"23776241"},{"id":"31244820-27221704-35366450","span":{"begin":278,"end":281},"obj":"27221704"},{"id":"31244820-24403862-35366451","span":{"begin":283,"end":286},"obj":"24403862"},{"id":"31244820-24403862-35366452","span":{"begin":359,"end":362},"obj":"24403862"},{"id":"31244820-23776241-35366453","span":{"begin":364,"end":367},"obj":"23776241"},{"id":"31244820-27221704-35366454","span":{"begin":394,"end":397},"obj":"27221704"},{"id":"31244820-24403862-35366455","span":{"begin":693,"end":696},"obj":"24403862"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"Along the same lines, others explored if direct antagonism of A2AR and A2BR would augment the antitumor effects of CT agents. Indeed, tumor-bearing mice treated with Doxorubicin (359, 405, 407), Dacarbazine (398), or Oxaliplatin (398, 407) in combination with A2AR (405), A2BR (359, 398), or dual A2AR/A2BR antagonists (407) displayed superior tumor control (398, 405, 407) or survived longer (359). Of note, tumors derived from mice treated with the combination of Dacarbazine and PSB1115, an A2BR antagonist, were more heavily infiltrated by CD8+ T cells as well as NKT cells and contained higher levels of GzB than tumors derived from counterpart mice subjected to Dacarbazine monotherapy (398). Likewise, concomitant administration of AB928, a dual A2AR and A2BR antagonist, along with Doxorubicin or Oxaliplatin increased the intra-tumoral detection of tumor-specific CD8+ T cells (407)."}

{"project":"TEST0","denotations":[{"id":"31244820-53-60-3850593","span":{"begin":179,"end":182},"obj":"[\"27221704\"]"},{"id":"31244820-58-65-3850594","span":{"begin":184,"end":187},"obj":"[\"23776241\"]"},{"id":"31244820-82-89-3850595","span":{"begin":208,"end":211},"obj":"[\"24403862\"]"},{"id":"31244820-104-111-3850596","span":{"begin":230,"end":233},"obj":"[\"24403862\"]"},{"id":"31244820-140-147-3850597","span":{"begin":266,"end":269},"obj":"[\"23776241\"]"},{"id":"31244820-152-159-3850598","span":{"begin":278,"end":281},"obj":"[\"27221704\"]"},{"id":"31244820-157-164-3850599","span":{"begin":283,"end":286},"obj":"[\"24403862\"]"},{"id":"31244820-233-240-3850600","span":{"begin":359,"end":362},"obj":"[\"24403862\"]"},{"id":"31244820-230-237-3850601","span":{"begin":364,"end":367},"obj":"[\"23776241\"]"},{"id":"31244820-233-240-3850602","span":{"begin":394,"end":397},"obj":"[\"27221704\"]"},{"id":"31244820-230-237-3850603","span":{"begin":693,"end":696},"obj":"[\"24403862\"]"}],"text":"Along the same lines, others explored if direct antagonism of A2AR and A2BR would augment the antitumor effects of CT agents. Indeed, tumor-bearing mice treated with Doxorubicin (359, 405, 407), Dacarbazine (398), or Oxaliplatin (398, 407) in combination with A2AR (405), A2BR (359, 398), or dual A2AR/A2BR antagonists (407) displayed superior tumor control (398, 405, 407) or survived longer (359). Of note, tumors derived from mice treated with the combination of Dacarbazine and PSB1115, an A2BR antagonist, were more heavily infiltrated by CD8+ T cells as well as NKT cells and contained higher levels of GzB than tumors derived from counterpart mice subjected to Dacarbazine monotherapy (398). Likewise, concomitant administration of AB928, a dual A2AR and A2BR antagonist, along with Doxorubicin or Oxaliplatin increased the intra-tumoral detection of tumor-specific CD8+ T cells (407)."}

{"project":"2_test","denotations":[{"id":"31244820-27221704-35366445","span":{"begin":179,"end":182},"obj":"27221704"},{"id":"31244820-23776241-35366446","span":{"begin":184,"end":187},"obj":"23776241"},{"id":"31244820-24403862-35366447","span":{"begin":208,"end":211},"obj":"24403862"},{"id":"31244820-24403862-35366448","span":{"begin":230,"end":233},"obj":"24403862"},{"id":"31244820-23776241-35366449","span":{"begin":266,"end":269},"obj":"23776241"},{"id":"31244820-27221704-35366450","span":{"begin":278,"end":281},"obj":"27221704"},{"id":"31244820-24403862-35366451","span":{"begin":283,"end":286},"obj":"24403862"},{"id":"31244820-24403862-35366452","span":{"begin":359,"end":362},"obj":"24403862"},{"id":"31244820-23776241-35366453","span":{"begin":364,"end":367},"obj":"23776241"},{"id":"31244820-27221704-35366454","span":{"begin":394,"end":397},"obj":"27221704"},{"id":"31244820-24403862-35366455","span":{"begin":693,"end":696},"obj":"24403862"}],"text":"Along the same lines, others explored if direct antagonism of A2AR and A2BR would augment the antitumor effects of CT agents. Indeed, tumor-bearing mice treated with Doxorubicin (359, 405, 407), Dacarbazine (398), or Oxaliplatin (398, 407) in combination with A2AR (405), A2BR (359, 398), or dual A2AR/A2BR antagonists (407) displayed superior tumor control (398, 405, 407) or survived longer (359). Of note, tumors derived from mice treated with the combination of Dacarbazine and PSB1115, an A2BR antagonist, were more heavily infiltrated by CD8+ T cells as well as NKT cells and contained higher levels of GzB than tumors derived from counterpart mice subjected to Dacarbazine monotherapy (398). Likewise, concomitant administration of AB928, a dual A2AR and A2BR antagonist, along with Doxorubicin or Oxaliplatin increased the intra-tumoral detection of tumor-specific CD8+ T cells (407)."}